Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Phase 4 Terminated 19 enrolled David Binion, MD Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelPrevention

Summary

The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.

Timeline

Start: 2021-10-14
Primary completion: 2024-04-24
Completion: 2024-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bezlotoxumab	Monoclonal antibody	10 mg/kg	Intravenous

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Summary

Timeline

Drugs

Indications